Procurement Opens for Next-Generation Plasma Virus Screening
New contract will supply viral RNA/DNA tests and automated analysers for plasma screening, reflecting wider investment in molecular diagnostics across Europe.
New contract will supply viral RNA/DNA tests and automated analysers for plasma screening, reflecting wider investment in molecular diagnostics across Europe.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.
A new Supply and Lease for Testing Equipment contract notice from Regionalne Centrum Krwiodawstwa i Krwiolecznictwa w Poznaniu points to a new phase of molecular virus testing in plasma. The centre plans to pair a steady flow of reagents with leased automated analysers, tightly linked to its IT systems, underlining how blood and laboratory services across Europe are reshaping diagnostics around nucleic acid detection.
Published on 14th January 2026, the Poznań notice sets out a clear objective: secure reagents and related materials “for detecting RNA and DNA viruses in plasma samples”, and lease equipment capable of carrying out those tests automatically. The combined scope covers both the chemistry of testing and the machinery that runs it.
Although the summary does not spell out individual virus types, the emphasis on RNA and DNA points directly to molecular diagnostics based on genetic material. That implies systems designed to pick up very low levels of viral genomes in plasma, supporting early detection and high sensitivity testing.
The planned solution has three main building blocks:
Automation is central. Rather than relying on manual handling, the leased equipment is expected to deliver end-to-end workflows, from sample loading through to result generation. The requirement for IT integration suggests a focus on traceability, data capture and reporting within the centre’s existing laboratory and administrative systems.
The notice excerpt does not provide contract value, duration or throughput volumes. But by bundling reagents, instruments and digital connectivity, the centre is signalling a long-term platform decision rather than a short, stand-alone purchase.
The Poznań procurement follows a model that has become common in molecular diagnostics: instead of buying analysers outright, the buyer leases them while committing to reagent supply. This approach shifts upfront capital costs into operating expenditure and ties equipment performance to the ongoing delivery of compatible kits.
Similar patterns are visible across Poland’s hospital and blood service tenders. In July 2025, Uniwersytecki Szpital Kliniczny im Jana Mikulicza-Radeckiego we Wrocławiu issued a contract notice for reagents for virological tests using real-time PCR on leased devices, allowing bids for either the whole order or specific packages. Here again, the analytical platform and the consumables are treated as a single ecosystem.
A similar configuration appears in the October 2025 procurement from Wojewódzki Specjalistyczny Szpital im. dr Wł. Biegańskiego w Łodzi, which sought the supply of reagents and media together with the lease of analysers for its Molecular Biology Laboratory, split into six packages with defined items and quantities.
Most recently, at the start of January 2026, Specjalistyczny Szpital im. dra Alfreda Sokołowskiego launched a contract for ongoing delivery of reagents, controls, fluids and accessories with equipment rental for transfusion immunology and microbiology tests. The Poznań centre’s strategy fits squarely within this shift to reagent-linked leasing deals.
For suppliers, these arrangements can offer predictable volumes and long-term customer relationships. For public buyers, they can ensure instrument availability, maintenance and upgrade options, but they also demand careful attention to pricing structures and the risk of dependency on a single technology provider.
The Poznań notice also reflects a wider tightening of molecular testing standards for plasma and blood-related services, both inside and beyond Poland.
In October 2025, Regionalne Centrum Krwiodawstwa i Krwiolecznictwa w Katowicach published a call for reagents and rented devices to run molecular biology tests for simultaneous detection of multiple viruses and for archiving plasma samples. Just days later, Regionalne Centrum Krwiodawstwa i Krwiolecznictwa im. prof. dr hab. Tadeusza Dorobisza we Wrocławiu sought reagents for detecting RNA HIV, RNA HCV and DNA HBV, plus controls, calibrators, consumables and the lease of two analysers.
Elsewhere, hospital laboratories are broadening their molecular scope. The Wojewódzki Szpital Specjalistyczny im. Św. Rafała w Czerwonej Górze tender from July 2025 covered the supply of a wide array of laboratory reagents and leased equipment, from acid–base and haematology testing through to microbiology and molecular diagnostics. In January 2026, Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego went to market for reagents and leased devices for haematology tests, alongside RNA isolation kits compatible with a specified automated system.
Beyond Poland, blood donor screening is a prominent driver. In December 2025, Unidade Local de Saúde de Gaia/Espinho, EPE in Portugal published a contract notice for reagents to monitor viral load using molecular biology and nucleic acid tests in blood donors. On the same month, Krajská nemocnice T. Bati, a. s. in the Czech Republic sought the ongoing supply of diagnostics for testing infectious markers in blood donors, including a free loan of an analyser and evaluation software.
National reference services are upgrading as well. In December 2025, the Bulgarian National Centre for Infectious and Parasitic Diseases (Natsionalen tsentŭr po zarazni i parazitni bolesti) tendered for a wide set of laboratory reagents and consumables spanning DNA/RNA isolation, PCR and sequencing kits across 36 positions, with stringent documentation requirements. In Greece, the hospital Γ.Ν.Α. «Ο Ευαγγελισμός-Πολυκλινική» tendered in November 2025 for reagents and equipment for molecular testing of hepatitis B, hepatitis C and HIV.
Taken together, these procurements show how molecular virology is becoming a standard layer in blood, plasma and infectious disease services. The Poznań centre’s emphasis on RNA/DNA detection and automation fits this trajectory, while its IT-integration requirement underlines a parallel digital consolidation.
The explicit call for integration with the ordering party’s IT systems is a notable element of the Poznań contract. It implies that the leased analysers must not operate as isolated boxes; they need to exchange data with laboratory information systems and, potentially, wider clinical or administrative platforms.
Other recent tenders echo this concern for connectivity and quality assurance. The notice from Szpital Specjalistyczny Chorób Płuc "Odrodzenie" im. Klary Jelskiej w Zakopanem in October 2025, for instance, seeks ongoing delivery of molecular diagnostics reagents and consumables while stressing compatibility with specific equipment and compliance with EU regulations. Such requirements, combined with IT linkages, are building more standardised, auditable testing environments.
For public laboratories, integrated systems can reduce transcription errors, speed up result reporting and support epidemiological monitoring. But they also demand careful procurement of interfaces, cybersecurity safeguards and long-term support arrangements, issues that are not detailed in the Poznań summary but will sit behind the IT integration requirement.
The Poznań centre’s move to procure reagents, automated analysers and IT-connected workflows for RNA/DNA virus detection is another marker of molecular methods becoming routine in plasma testing. It sits alongside a cluster of recent tenders across Poland and the wider region that combine reagent supply, equipment leasing and digital connectivity.
Key points to watch as this and similar procurements progress will include the balance between flexibility and vendor lock-in in leasing arrangements, how quickly laboratories can standardise on new platforms, and the extent to which integrated molecular systems feed into wider surveillance and quality frameworks. For now, the direction is clear: public-sector laboratories are investing heavily in molecular, automated and connected diagnostics for viral safety.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.